fjrigjwwe9r0Board:Content
Bone loss is a major health concern
for postmenopausal women
New clinical research indicates that Douglas Laboratories' Ultra-Ostivone TM formula lowers N-linked telopeptides (NTx), an important marker in measuring bone loss.
The loss of bone density with advancing age is a serious health concern of our population. The results of a recently completed placebo-controlled trial of Ultra-Ostivone TM , a dietary supplement containing ipriflavone, demon-strate a dramatic reduction in urinary N-linked telopeptides (NTx), a dynamic indicator of bone breakdown.
This research on Ultra-Ostivone TM is the first to demonstrate an effect of an ipriflavone-containing supplement on NTx levels. Measurement of NTx levels provides the physician with a rapid assessment of treat-ment efficacy in the fight against bone loss.
Details of the study
The study involved postmenopausal women not currently receiving hormone replacement therapy. Subjects received either Ultra-OstivoneTM or a placebo for a 3-month period. Women received 2 capsules of Ultra-Ostivone TM daily supplying:
600 mg of ipriflavone
300 mg of calcium
100 I.U. of vitamin D Urinary NTx levels were measured before and after treatment.
|
A reduction in the NTx level represents a beneficial outcome for post-menopausal women.
|
Results
Women receiving Ultra-Ostivone TM experienced a 29% decrease in NTx levels while those receiving the placebo experienced an increase. The results of this study confirm the findings of other researchers that demonstrate the usefulness of ipriflavone at slowing the progression of bone loss in postmenopausal women.
Refer to the chart below for previous research study results on the ability of ipriflavone to prevent the decline in bone loss commonly seen after menopause.
Previous research on the effect of Ipriflavone in bone loss. |
. |
Treatment |
| Vertabral Bone Density |
Study 1 2 |
Ipriflavone 600 mg/day |
No Change |
. |
Placebo |
Decrease |
Study 2 3 |
Ipriflavone 600 mg/day |
Increase |
. |
Placebo |
Decrease |
Study 3 4 |
Ipriflavone 600 mg/day |
No Change |
. |
Placebo |
Decrease |
References
1) Halpner, A. D., Kellermann, G., Ahlgrimm, M. J. et al. The Effect of an Ipriflavone-Containing Supplement on Urinary N-Linked Telopeptide Levels in Postmenopausal Women. J Womens Health Gender Based Med In Press.
2) Gennari, C., Agnusdei, D., Crepaldi, G. et al. Effects of ipriflavone - a synthetic derivative of natural isoflavones - on bone mass loss in the early years after menopause. Menopause 1998;5:9-15.
3) Agnusdei, D., Crepaldi, G., Isaia, G., et al. A double blind, placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss. Calcif Tissue Int 1997;61:142-147.
4) Gennari, C., Adami, S., Agnusdei, D. et al. Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass. Calcif Tissue Int 1997;61:S19-S22.
Ostivone¢ç is a trademark of Technical Sourcing International
|